ALSO NOTED: Wyeth wins FDA blessing for hemophilia med; India considers compulsory licensing;

> Wyeth got the FDA's nod for its hemophilia drug Xyntha, which also got the green light to prevent surgical bleeding in patients with the disease; the company was named in a related patent infringement lawsuit filed by rival Novartis. Report

> India is considering issuing compulsory licenses for generic versions of two cancer drugs--Roche's Tarceva and Pfizer's Sutent--to be made in India and exported to Nepal, which cannot afford the drugs nor manufacture them. Report

> New research suggests that Crohn's disease patients should start with biologic drugs such as Johnson & Johnson's Remicade rather than reserving them for use after steroids and other remedies fail. Report

> PDL BioPharma has agreed to sell a Minnesota plant to Genmab for $240 million cash; the new owner plans to keep the facility's 170 workers. Report

> Endo Pharmaceuticals posted fourth-quarter profits of $50.6 million, more than triple its previous-period results; accounting charges weighed down the company's 4Q 2006 numbers. Report

> Ipsen got backing from Europe's Committee for Medicinal Products for Human Use for its gout drug Adenuric. Report

> Antisoma is sending out signals that it's looking for new acquisitions to add to its pipeline. Report

> Researchers at Novocell report a key breakthrough in their program to find a cure for diabetes. The company reports that the researchers were able to turn embryonic stem cells into insulin-producing cells in mice. Report

> The blog Eye on FDA sees lessons in the high number FDA approvable letters. Report

And Finally... Computers spot Alzheimer's more quickly and accurately than docs do. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.